ASSESSING THE SAFETY AND EFFICACY OF A 2MG DOSE OF TH9507, A GROWTH HORMONE RELE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该研究的主要目的是确定药物TH 9507（一种生长激素释放因子）在减少与HIV脂肪代谢障碍相关的过度内脏肥胖方面的安全性和有效性。 次要目的包括总胆固醇/HDL比率、甘油三酯水平的改善、IGF-1的变化和生活质量的改善以及TH 9507治疗在具有过量腹部脂肪积累的HIV受试者中的安全性特征的表征。 接受抗逆转录病毒治疗的HIV感染患者通常表现出身体成分变化和代谢异常，称为HIV脂肪营养不良综合征。 在这一人群中，内脏肥胖的增加与血脂异常、高胰岛素血症和糖耐量受损有关。 生长激素水平降低被认为是腹部肥胖和代谢紊乱之间的潜在联系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of the stduy is to determine the safety and efficacy of the medication TH9507, a growth hormone releasing factor, in reducing excess visceral adiposity associated with HIV lipodystrophy. Secondary objectives include improvements in total cholesterol/HDL ratio, triglyceride levels, changes in IGF-1 and improvement in quality of life and characterization of the safety profile of TH9507 treatment in HIV subjects with excess abdominal fat accumulation. HIV infected patients treated with antiretroviral therapy commonly exhibit body composition changes and metabolic abnormalities, termed the HIV lipodystrophy syndrome. Increased visceral adiposity has been associated with abnormal lipid profiles, hyperinsulinemia and impaired glucose tolerance in this population. Reduced growth hormone levels have been implicated as a potential link between abdominal obesity and metabolic disturbances.